secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001815776-24-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics reports Q1 net loss $16.6M; positive Phase 3 presbyopia data, NDA on track mid-2024
--------------------------------------------------------------------------------

- Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.
- Phase 3 CLARITY study for LNZ100 met all primary/secondary endpoints; 84% achieved ≥4 lines near vision improvement.
- NDA submission to FDA for LNZ100 planned for mid-2024; commercial launch as early as H2 2025.
- Completed merger with Graphite Bio and concurrent $53.5M private placement in March 2024.
- Jeff George appointed Chairman; Dan Chevallard CFO; commercial buildout underway including third-party logistics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/0001815776-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000039/lenz-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer